Kornimate/medical-research-clean huggingface dataset:
the effect of solving jigsaw puzzles on visuospatial cognition in older adults: jigsaw puzzles as cognitive enrichment

Conditions: Cognitive Impairment

Summary: meta-analyses indicate beneficial effects of cognitive training and cognitively challenging video games on cognition. however, cognitive effects of solving jigsaw puzzles - a popular, visuospatial cognitive leisure activity - have not been investigated, yet. thus, the primary aim of this study is to evaluate the effect of solving jigsaw puzzles on visuospatial cognition. as secondary aims, effects on psychological outcomes (self-efficacy, perceived stress, well-being) and visuospatial everyday functioning (instrumental activities of daily living and self-reported cognitive failures in everyday life) are examined.

see references section below for the study protocol article

Eligibility criteria:
inclusion criteria: * no cognitive impairment (mini-mental state examination ≥ 24) * commitment to minimum jigsaw puzzle time (1 hour/day, 6 days/week, 5 weeks) * interest in jigsaw puzzles * low jigsaw puzzle experience (less than 5 completed puzzles within the last 5 years) exclusion criteria: * cognitive impairment (mini-mental state examination \< 24) * participation in another interventional study * self-reported psychiatric, neurologic or other disease, which could affect cognitive change over time * self-reported, severe visual impairment or motoric impairment of the upper extremity which significantly affects ability to solve jigsaw puzzles

Keywords: cognition cognitive aging dementia neurocognitive disorders cognitive therapy cognitive reserve cognitive enrichment jigsaw puzzles
universal screening for maternal depression with the chica system

Conditions: Maternal Depression

Summary: the chica system is a clinical decision support system that uses adaptive turnaround documents to provide point-of-care information to clinicians. we will be studying whether it can help in the diagnosis and referral of mothers with maternal depression.


Eligibility criteria:
inclusion criteria: * all families of patients age 0 to 15 months exclusion criteria: * none

Keywords: maternal depression clinical decision support
study evaluating allergic reactions to benefix in hemophilia b patients

Conditions: Hemophilia B

Summary: based on the finding that anaphylactic reactions to benefix ("fix") are associated with a specific ige, a basophil histamine release assay was selected to evaluate and demonstrate subject sensitization to fix.


Eligibility criteria:
inclusion criteria: study group: * written informed consent or assent, as applicable. * subjects with moderate to severe hemophilia b (fix:c \<5%), who have reported class ii or class iii allergic manifestations within 24 hours of a benefix infusion. control group: * written informed consent or assent, as applicable. * subjects with moderate to severe hemophilia b (fix:c \<5%) exclusion criteria: study group: * subjects who had no reaction when rechallenged with benefix, in the absence of prophylactic immunomodulating therapy. * subjects whose most recent allergic manifestations with benefix occurred \>36 months prior to providing written informed consent for this study. * subjects who have taken antihistamine, steroidal, or other immunosuppressive therapy within 72 hours of the scheduled visit for this study. * subjects with immune disorders. * subjects unable to comply with a minimum 5-day fix washout requirement. control group: * subjects with documented evidence of prior allergic reaction to any fix product. * subjects with documented evidence of prior or current fix inhibitor (bu \>0.6). * subjects have taken antihistamine, steroidal, or other immunosuppressive therapy within 72 hours of the scheduled study blood draw. * subjects with immune disorder. * subjects unable to comply with a minimum 5-day fix washout requirement.

Keywords: hemophilia b allergic reaction
oral dronabinol-hiv

Conditions: HIV

Summary: the purpose of this study is to define the mechanisms of cannabis on the genome of people with hiv who use cannabis. the investigator aims to better understand the effect of dronabinol on immune and inflammatory functions, and whether these changes are hiv-status dependent. this research may better inform public health policy regarding cannabis use. depending on the results, additional studies may also build upon this research to develop more effective and specific treatments for cannabis use associated disorders.


Eligibility criteria:
pwh inclusion criteria: * current or past cannabis use. * hiv-positive on antiretroviral therapy. * meet criteria of viral suppression (viral load less than approximately 400 copies/ml). * good physical and mental health as determined by history, the scid, collateral information, physical and laboratory examinations, ecg, and vital signs. * women of childbearing potential: must agree to use or have their partner use one acceptable method of birth control throughout the study, at the discretion of the principal investigator. pwoh inclusion criteria: * current or past cannabis use. * good physical and mental health as determined by history, the scid, collateral information, physical and laboratory examinations, ecg, and vital signs. * women of childbearing potential: must agree to use or have their partner use one acceptable method of birth control throughout the study, at the discretion of the principal investigator. exclusion criteria: * cannabis naïve individuals. * under the age of 18 years. * unable to provide written informed consent. * unable to read or write in english. * unable to tolerate the effects of smoking approximately half a joint of cannabis (or equivalent), at the discretion of the principal investigator. * major or clinically unstable medical conditions (e.g., myocardial infarction, hypertension, clinically significant head injury or loss of consciousness). * iq less than 80. * diagnosis of psychosis confirmed by scid. * other medical, psychiatric, or psychosocial history that is deemed unsuitable for participation in study per pi. * has donated blood within the last 8 weeks. * sesame oil allergy. * concomitant use of other drugs that cause dizziness, confusion, sedation, or somnolence such as cns depressants (e.g., barbiturates, benzodiazepines, ethanol, lithium, opioids, buspirone, scopolamine, antihistamines, tricyclic antidepressants, other anticholinergic agents, muscle relaxants). * patients with cardiac disorders or concomitant use of other drugs that are associated with similar cardiac effects (e.g., amphetamines, other sympathomimetic agents, atropine, amoxapine, scopolamine, antihistamines, other anticholinergic agents, amitriptyline, desipramine, other tricyclic antidepressants). * patients with a history of seizures, including those receiving anti-epileptic medication or with other factors that can lower the seizure threshold.
telemedicine education for caregivers and asthma control in children

Conditions: Uncontrolled Asthma; Telemedicine-Based Education

Summary: asthma control in pediatric patients remains a critical issue for healthcare providers. telemedicine has emerged as an effective solution for overcoming distance barriers in healthcare delivery. this study aims to utilize telemedicine-based education for caregivers to improve asthma control in children with uncontrolled asthma. by providing remote guidance and support, the study seeks to enhance caregivers' knowledge and management practices, ultimately leading to better asthma outcomes for pediatric patients.


Eligibility criteria:
inclusion criteria: * pediatric asthma patients diagnosed according to the gina guidelines, classified as having uncontrolled asthma, are managed and followed up for at least 1 month at the pediatric asthma unit of the outpatient department. exclusion criteria: * pediatric patients who do not cooperate or are unable to complete the childhood asthma control test questionnaire. * caregivers who cannot complete the questionnaires related to the assessment of asthma control and associated factors. * pediatric patients who have siblings participating in the study. * patients currently participating in another clinical study (excluding non-interventional studies or registries).

Keywords: asthma pediatrics telemedicine uncontrolled asthma
evaluation of the efficacy of systemic treatments for alopecia (estaa)

Conditions: Alopecia Areata

Summary: the aim of our study was to retrospectively assess the efficacy and safety of systemic treatments in patients with alopecia areata, by recruiting cases from the hugo network (hôpitaux universitaires du grand ouest), a network of 5 hospitals : brest, nantes, rennes, angers and tours.


Eligibility criteria:
inclusion criteria: * patient with severe alopecia * has received at least one systemic treatment for at least 3 months (among methotrexate, intravenous or oral corticosteroid therapy, ciclosporin, uva/uvb phototherapy) * patient affiliated to a social security scheme * age greater than or equal to 18 years exclusion criteria: * patients under legal protection (guardianship, curatorship, etc.) * refusal to participate * other cause of alopecia * follow-up less than 3 months * age under 18 years

Keywords: severe
effectiveness of decision support for cardiovascular risk management in people with cardiovascular disease

Conditions: Atherosclerotic Cardiovascular Diseases; Shared-decision Making

Summary: this study aims to improve the way patients with cardiovascular diseases are informed about their treatment options. it explores methods to support shared decision-making between patients and doctors. in some cases, doctors will take extra time to discuss treatment options in detail. to assess the impact, some patients will be asked to complete questionnaires after their clinic visits.


Eligibility criteria:
inclusion criteria: * established ascvd * at least 30 days since last cvd event and/or the diagnosis of ascvd. if no cvd events have occurred, imaging confirming ascvd must have been conducted at least 30 days prior. * documented ascvd (defined according to the 2021 european society of cardiology guideline), which includes ascvd established clinically or demonstrated unequivocally by imaging: * clinically documented ascvd includes previous myocardial infarction, acute coronary syndrome, coronary revascularization (percutaneous coronary intervention (pci) or coronary artery bypass surgery (cabg)), and other arterial revascularization procedures, ischemic stroke or transient ischemic attack, and peripheral artery disease (from fontaine stage ii). angina pectoris (stable) without imaging evidence of atherosclerosis does not qualify as ascvd. * ascvd unambiguously identified through imaging, includes significant stenosis (\>50%) on coronary angiography, computed tomography angiography, or carotic ultrasound. it also includes aortic aneurysms measuring ≥3cm. only carotid intima-media thickness measurements (cimt), coronary artery calcium scoring or abnormal ankle-brachial index scores without evidence of stenosis, do not qualify as ascvd. * age 40-80 years (to allow for individual risk predictions with the smart2 model * patient attending the cardiology or vascular medicine outpatient clinic * sufficient understanding of the dutch language (due to the questionnaires being administered in dutch). * written informed consent must be provided. although the proposed intervention is not subject to the wmo, informed consent is required for the collection and processing of data, including the distribution of questionnaires. exclusion criteria: * patients currently participating in other interventional medication studies, or studies that directly affect the therapy plan * remaining life expectancy of less than 2 years as assessed by a consulting healthcare professional (these patients have no indication for cardiovascular risk management) * patients for whom individual risk predictions with the smart2 model are not feasible: * systolic blood pressure (sbp) \ 200 mmhg * total cholesterol \ 8 mmol/l * high-density lipoprotein (hdl) cholesterol \ 2.5 mmol/l * low-density lipoprotein (ldl) \ 7.4 mmol /l * estimated glomerular filtration rate (egfr) \<30ml/min/1.73m2 or dialysis * active treatment for malignity, pregnancy, history of organ transplantation, or liver failure * previous participation in 2-decide
exploration of mechanisms for weaning failure

Conditions: Weaning Failure; Central Respiratory Depression; Diaphragm Injury; Phrenic Nerve Disorder

Summary: this study is a prospective physiologic study. the primary study population will be adult invasive tracheal intubated patients with copd, and investigators will collect relevant demographic data, vital signs, and baseline physiologic parameters of the patients prior to the spontaneous breathing test（sbt). the participants will be divided into a successful withdrawal group and a failed withdrawal group according to the sbt outcome, and the changes in the above parameters during sbt will be compared between the two groups .

this observational study mainly include participants who had invasive mechanical ventilation for ≥48 h and are assessed to be ready for the sbt trial.the sbt approach is based on the low-level pressure support mode. prior to the sbt trial, baseline demographic and physiologic data of the participants will be collected, and the participants will be divided into two groups based on the results of the sbt trial: successful and unsuccessful, and the physiologic changes during the sbt trial will be compared between the two groups, respectively.

Eligibility criteria:
inclusion criteria: * invasive mechanical ventilation for at least 48 hours exclusion criteria: * neuromuscular disease；postoperative patients or patients with traumatic brain injury
maximizing the dietary pattern of older adults: the effects of protein intake on protein kinetics

Conditions: Sarcopenia

Summary: a randomized study to demonstrate how animal-based protein-rich food sources can be used by older adults to increase protein intake within pre-existing dietary patterns.

current dietary patterns of older americans will be augmented by readily available quality protein sources. investigators will observe the effects of recommended and common protein intakes on the maintenance of whole-body protein balance and potential for muscle protein anabolism. 3 groups of 10 older subjects will be studied during daily protein intakes. study duration per subject will be about 2 weeks.

Eligibility criteria:
inclusion criteria: * bmi ≤ 35 kg/m2 * capable of providing informed consent * covid-19 negative and/or asymptomatic exclusion criteria: * subject who does not/will not eat animal protein sources. * body mass index \> 35. * history of chemotherapy or radiation therapy for cancer in the 6 months prior to enrollment. * use of insulin to control blood sugar level. * currently receiving androgen (e.g., testosterone) or anabolic (e.g., gh, igf-i) therapy. * currently using prescription blood thinning medications. * unable or unwilling to suspend aspirin use for 7 days prior to visit 3. * unwilling to avoid using protein or amino-acid supplements during participation.

Keywords: muscle loss protein animal-based protein
solution focused coaching strategy within a paediatric multidisciplinary neuromuscular clinic

Conditions: Neuromuscular Diseases

Summary: the purpose of this study is to implement solution focused coaching in pediatric rehabilitation (sfc-peds) within the multidisciplinary neuromuscular clinic at holland bloorview kids rehabilitation hospital and evaluate its effect on children's ability to set and attain personally meaningful goals. a secondary goal is to determine the impact of sfc-peds on self-determination in children with neuromuscular conditions. this study aims to compare two methods of scf-peds delivery, a single coaching session vs. intensive coaching (5 sessions) on goal attainment. this study will also help researchers and clinicians understand the types of goals that are set by children with neuromuscular conditions. lastly, this study is going to explore with the participants their perception of the feasibility of using this methodology within a clinical context.

nationally, standards of care have been published for paediatric neuromuscular (nm) conditions to optimize care, improve quality of life and increase life span. children with nm conditions are followed in regional multidisciplinary clinics in ontario and across canada. at each visit they can be seen by 8 health care providers each focusing on and making recommendations for the different aspects of their care. currently, there are no evidenced based interventions for children with nm conditions evaluating the ability of children to set and attain their care goals and/or other personally meaningful goals. self-determination is defined as the ability to "use skills, knowledge and beliefs that enable a person to engage in goal directed, self-regulated, autonomous behavior." the development of self-determination is a process that begins in childhood. solution focused coaching (sfc) is a strengths- based, client-centered approach to service delivery that supports clients to build on their existing capacity to move closer to meaningful goals. this study will evaluate the impact of sfc on goal setting, achievement and self determination in children with nm conditions.

Eligibility criteria:
inclusion criteria: * child has a primary nm diagnosis * child ages 10-18 years * child able to converse orally in english * child has a willingness to engage in the coaching intervention * child is aware that they have a neuromuscular condition * child is followed clinically in the neuromuscular clinic at holland bloorview kids rehabilitation hospital at 4-6 month intervals * child has internet access at home and a device to connect to the internet with a camera * child is able to demonstrate capacity to consent * parent is able to read and write in english exclusion criteria: -child has a moderate to severe intellectual disability

Keywords: solution focused coaching self determination
to find the best dose of pvgi.1(vegf2) to benefit angina patients when given with an experimental injection catheter

Conditions: Angina Pectoris

Summary: the purpose of this study is to determine the optimum effective dose of recombinant plasmid dna \[pvgi.1(vegf2)\] gene therapy administered using an experimental cardiac direct injection catheter (stiletto™) system needed to benefit patients with severe angina pectoris.


Eligibility criteria:
inclusion criteria: * are willing and able to give informed consent * have ccs class iii or iv angina refractory to optimized medical therapy * experience signs or symptoms of angina during the exercise tolerance test (ett) * have identified area(s) of reversible ischemic myocardium * have procedurally acceptable targeted treatment zones exclusion criteria: * have exercise-limited non-cardiac chest discomfort * unwilling or unable to undergo exercise testing * able to exercise greater than 6 minutes on the treadmill * are candidates for conventional revascularization procedures * are or have been enrolled within 30 days, in another experimental study * have had the most recent angiogram more than 6 months prior to screening * previously received an investigational angiogenic agent * have another disease severe enough to limit exercise test or place patient at risk * have uncontrolled: atrial fibrillation, atrial flutter, and/or significant arrhythmias * have evidence of left ventricular aneurysm or ventricular thrombus * are unwilling or unable to undergo cardiac catheterization or nuclear testing procedures * have had a q-wave mi, within 60 days * have severe aortic valve stenosis or have a mechanical aortic or mitral valve * have unstable angina or an acute non-q-wave myocardial infarction within 14 days * have had a documented stroke or transient ischemic attack within 60 days * are pacemaker dependent * have a recent history of active diabetic retinopathy or age-related wet macular degeneration * have a history of cancer within the last 5 yrs. or have current evidence of a malignant neoplasm * have a history of alcohol or drug abuse within 90 days * are pregnant or lactating * have reproductive potential and are unwilling to use condoms for contraception for 1 year after treatment - both male and female * are unable to return to the clinic for the scheduled follow-up appointments * are taking medications which may produce an undue risk * have areas of lv wall less than 6mm thick

Keywords: dna circular gene therapy
long-term respiratory muscle strength in young covid-19 patients

Conditions: COVID-19

Summary: the coronavirus disease 2019 (covid-19) is a highly contagious disorder caused by the severe acute respiratory syndrome coronavirus 2 (sars-cov-2). covid-19 is a multisystem disease and therefore presents a variety of symptoms in the acute phase, such as fever, dry cough, fatigue, sore throat, loss of taste or smell, shortness of breath, nasal congestion, chest pain, muscle or joint pain, headache, and nausea. covid-19 primarily affects the respiratory functions of individuals. although this situation is more difficult in hospitalized patients, it also causes severe effects in individuals who recover with home medication. it is thought that this damage caused by covid-19 may cause permanent effects on individuals in the long term. during the covid-19 period, individuals also had to maintain an inactive lifestyle due to quarantine. this decrease in physical activity capacity also causes permanent damage to the respiratory functions of individuals. in addition, studies have focused on this population, as covid-19 usually affects older individuals. however, considering that young people are also exposed to the covid-19 virus, the effect on respiratory functions in these individuals should also be examined. combined with the available information on pulmonary functions, there is insufficient evidence about extrapulmonary features in post-covid-19 patients who survive mild illness in the long term. it is also necessary to examine whether there is permanent damage to extrapulmonary features such as peripheral muscle strength in these individuals. therefore, in our study, it is aimed to examine the long-term results of respiratory functions, respiratory muscle strength and peripheral muscle strength of young individuals who recovered from covid-19 and recovered from mild disease.


Eligibility criteria:
inclusion criteria: patients: * diagnosed with covid-19, with a positive polymerase chain reaction (pcr) test * at least six months ago (long term) * non-hospitalization due to covid-19 * non-smoker / for ex-smokers with 10 pack x years or less of smoking * not continuing any regular physical activity program controls: * non-smoker / for ex-smokers with 10 pack x years or less of smoking, * not continuing any regular physical activity program * willing to participate to the study exclusion criteria: * receiving inpatient or intensive care treatment due to covid-19 * having acute infection * previous pulmonary resection or cardiac surgery * having lung or heart comorbidities such as asthma * chronic obstructive pulmonary disease (copd) and heart failure * uncontrolled hypertension * history of malignancy * neurological disease (e.g., alzheimer, multiple sclerosis, parkinson) * rheumatologic diseases

Keywords: covid-19 muscle strength pulmonary function physical activity dyspnea